Latest Headlines

Latest Headlines

Medtronic and Covidien to close $43B merger today with Irish High Court approval

Weeks after Medtronic and Covidien won shareholder approval for their $43 billion merger, the companies expect to finalize the deal today after the Irish High Court signed off on the pending acquisition.

In a win for Spectranetics, Covidien's to-be-divested drug-coated balloon earns CE mark

Covidien today announced the CE mark granted for its Stellarex drug-coated balloon for peripheral artery disease. In addition to physically displacing the lesion with angiopolasty, Stellarex delivers the drug paclitaxel like many of its European competitors.

Medtronic and Covidien win shareholder approval for proposed $43B merger

Medtronic and Covidien are nearing the finish line of their pending $43 billion merger as Medtronic shareholders voted on Tuesday to approve the deal, following in the footsteps of a similar vote from Covidien shareholders. 

Covidien (and Medtronic) have high hopes for the lung cancer treating superDimension

Covidien is working on a new version of its superDimension device that can eliminate the need for a bloody incision when performing a lung biopsy.

UPDATED: FDA approves Medtronic's drug-coated balloon, setting up clash with Bard in new U.S. market

The FDA gave PMA approval to Medtronic's IN.PACT Admiral drug-coated balloon for the treatment of peripheral artery disease in the upper leg, making it a competitor to C.R. Bard's recently approved Lutonix 035 balloon.

Covidien, Stryker tout stroke study that used their stents

A comparative study found that treatment of stroke using stent thrombectomy devices manufactured by Covidien and Stryker is twice as effective as treatment using medication alone.

Med tech M&A deal value up 6-fold in 2014

This has been a good year for M&A in the medical device industry. The number of deals rose 39% to 57 announced transactions. Moreover, deal value more than sextupled to $86 billion, up from $14 billion in 2013.

IRS battles it out with Medtronic and Covidien over offshore tax paying tactic

As lawmakers and regulators crack down on med tech companies launching corporate inversions for tax-paying purposes, the U.S. Internal Revenue Service is zeroing in on another tactic used by devicemakers like Medtronic and Covidien to guard offshore earnings and avoid steep domestic tax rates.

Covidien loses battle in patent war with J&J as top U.S. patent court throws out $176M award

Covidien lost a battle in its years-long patent war with Johnson & Johnson's Ethicon unit, as a top U.S. patent appeals court tossed out a $176 million award for the company and ruled that its claims regarding J&J/Ethicon's Harmonic line ultrasonic surgical tools were invalid.

Medtronic sells $17B in bonds to fund Covidien buy

Medtronic has sold $17 billion in bonds to fund its $43 billion acquisition of Covidien that's still expected to close early next year. The medical device giant had been expecting to fund the deal mostly with ex-U.S. cash, but opted instead for debt in order to avoid potential issues with U.S. regulators seeking to crack down on tax inversion deals.